TGFB1 and Hepatic fibrosis: Targeting the TGF-β pathway can attenuate liver fibrosis in several preclinical animal models [58]; however, the development and translation of TGF-β-based therapies to treat human patients face significant challenges due to the cell-type-dependent pleiotropic roles of TGF-β.